Illuminare Biotechnologies Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$4.5M
- Investors
-
5
Illuminare Biotechnologies General Information
Description
Developer of an intra-operative nerve visualization technology intended to reduce the risk of nerve damage. The company's technology binds specifically to myelin and illuminates to make nerves, fat, muscles, and blood vessels more visible, enabling surgeons with improved visibility during operations.
Contact Information
Website
www.illuminarebio.comCorporate Office
- 325 Saint Marks Avenue
- Brooklyn
- New York, NY 11238
- United States
Corporate Office
- 325 Saint Marks Avenue
- Brooklyn
- New York, NY 11238
- United States
Illuminare Biotechnologies Timeline
Illuminare Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 07-May-2026 | $4.5M | Completed | Clinical Trials - Phase 2 | ||
| 4. Secondary Transaction - Private | 01-Jan-2026 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series B) | 15-May-2023 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 18-Aug-2017 | $2.37M | $2.37M | Completed | Stealth | |
| 1. Early Stage VC | 10-Jun-2016 | Completed | Stealth |
Illuminare Biotechnologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B-2 | ||||||||
| Series A | 7,100,000 | $0.000001 | 5% | $0.38 | $0.38 | 1x | $0.38 | 11.24% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Illuminare Biotechnologies Comparisons
Industry
Financing
Details
Illuminare Biotechnologies Competitors (1)
One of Illuminare Biotechnologies’s competitors is Alume Biosciences, a Venture Capital-Backed company based in La Jolla, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alume Biosciences | Venture Capital-Backed | La Jolla, CA |
Illuminare Biotechnologies Signals
Illuminare Biotechnologies Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Band of Angels | Angel Group | Minority | ||
| Livewire Mobile | Corporation | Minority | ||
| Three B Holdings | Family Office | Minority | ||
| Endo Investors | Venture Capital | Minority | ||
| Thylacine Capital | Venture Capital | Minority |
Illuminare Biotechnologies FAQs
-
When was Illuminare Biotechnologies founded?
Illuminare Biotechnologies was founded in 2016.
-
Where is Illuminare Biotechnologies headquartered?
Illuminare Biotechnologies is headquartered in New York, NY.
-
What is the size of Illuminare Biotechnologies?
Illuminare Biotechnologies has 5 total employees.
-
What industry is Illuminare Biotechnologies in?
Illuminare Biotechnologies’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Illuminare Biotechnologies a private or public company?
Illuminare Biotechnologies is a Private company.
-
What is the current valuation of Illuminare Biotechnologies?
The current valuation of Illuminare Biotechnologies is .
-
What is Illuminare Biotechnologies’s current revenue?
The current revenue for Illuminare Biotechnologies is .
-
How much funding has Illuminare Biotechnologies raised over time?
Illuminare Biotechnologies has raised $11M.
-
Who are Illuminare Biotechnologies’s investors?
Band of Angels, Livewire Mobile, Three B Holdings, Endo Investors, and Thylacine Capital have invested in Illuminare Biotechnologies.
-
Who are Illuminare Biotechnologies’s competitors?
Alume Biosciences is a competitor of Illuminare Biotechnologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process